- Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
-
Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ
- KMID: 1782015
- J Korean Med Sci.
- 2009 Oct;24(5):910-917.
- doi: 10.3346/jkms.2009.24.5.910
We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as firs-tline chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Paclitaxel-Coated Balloon Treatment and Plain Old Balloon Angioplasty for De Novo Coronary Lesions
-
Her AY, Ann SH, Singh GB, Kim YH, Yoo SY, Garg S, Koo BK, Shin ES
- KMID: 2374037
- Yonsei Med J.
- 2016 Mar;57(2):337-341.
- doi: 10.3349/ymj.2016.57.2.337
PURPOSE: This study compared the angiographic outcomes of paclitaxel-coated balloon (PCB) versus plain old balloon angioplasty (POBA) treatment for de novo coronary artery lesions. At present, there is no available... -
- CITED
-
- Close
- SHARE
-
- Close
